Persistence of protein oxidation products and plasma antioxidants in juvenile idiopathic arthritis. A one-year follow-up study

• Published in: Clinical and experimental rheumatology Vol. 25; no. 1; pp. 112 - 114
• Main Authors: RENKE, J, SZLAGATYS, A, HANSDORFER-KORZON, R, SZUMERA, M, KAMINSKA, B, KNAP, N, POPADIUK, S, SZARSZEWSKI, A, WOZNIAK, M
• Format: Journal Article
• Language: English
• Published: Pisa Clinical and Experimental Rheumatology 2007
• Subjects: Adolescent; Arthritis, Juvenile - blood; Arthritis, Juvenile - drug therapy; Biological and medical sciences; Case-Control Studies; Child; Child, Preschool; Diseases of the osteoarticular system; Female; Follow-Up Studies; Glutathione Peroxidase - blood; Glutathione Peroxidase - drug effects; Humans; Inflammatory joint diseases; Male; Medical sciences; Protein Carbonylation - drug effects; Superoxide Dismutase - blood; Superoxide Dismutase - drug effects; antioxidants; Diseases of the osteoarticular system; Juvenile rheumatoid arthritis; Inflammatory joint disease; Antioxidant; juvenile idiopathic arthritis; Protein; Blood plasma; Persistence; Chronic; Follow up study; protein oxidation; Oxidation
• ISSN: 0392-856X; 1593-098X

Plasma protein oxidation products and blood antioxidants, like superoxide dismutase (SOD), glutathione peroxidase (GPx) and total antioxidant status (TAS) were investigated in children with juvenile idiopathic arthritis (JIA) in a year follow-up study.
Carbonyl group content within plasma proteins, activity of red blood cell SOD and GPx, as well as the blood TAS level were determined in 14 children with JIA twice, namely at the admission to the hospital (Time 0 = T0) and then after a year of treatment (Time 1 = T1).
An increased level of plasma protein carbonyls was observed in both assessments (T0 and T1) as compared to control. However there was no significant difference in plasma carbonyls level between the initial (T0) and final (T1) examination of the patients. Similarly, SOD activity was higher in children with JIA as compared to control subjects and did not change significantly after a year of follow-up. Red blood cell GPx activity remained within the normal range throughout the study. Interestingly, the blood TAS level was initially comparable to control and rose significantly after the year of treatment.
A level of plasma protein oxidation products remains significantly higher in children with JIA as compared to healthy subjects. The lack of accumulation of plasma protein carbonyls may result from efficient proteolysis in childhood and/or adaptive increase of the blood TAS level in the course of effective anti-inflammatory therapy. Analysis of plasma oxidative stress markers and antioxidant potential of the blood might be helpful in monitoring the clinical treatment of children suffering from JIA.